This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.
Is male or female aged two months (50 to 70 days inclusive) on the day of the first dose of study vaccine.
Is born at full term of pregnancy (≥37 weeks of gestation) with a birth weight of ≥2.5 kg.
Has a history of diphtheria, tetanus, pertussis, poliovirus, Hep B, or Hib infection.
Has a known SARS-CoV-2 infection at Screening.
Was born to a mother with a known history of Hep B infection based on HBsAg seropositivity.
Was born to a mother with a known history of HIV infection based on HIV antibody seropositivity.